



## Pneumococcal Vaccines Work Group

**April 2025, ACIP meeting**

April 15, 2025

Miwako Kobayashi

National Center for Immunization and Respiratory Diseases

# Pneumococcal Vaccines Work Group

## ACIP Members

- Jamie Loehr (Chair)
- Mini Kamboj
- George Kuchel
- Robert Schechter

## Ex Officio Members

- Tina Mongeau (FDA)
- Nick Geagan (FDA)
- Uzo Chukwuma (IHS)
- Mamodikoe Makhene (NIH, primary)
- Meenu Upadhyay (NIH, alternate)
- Risa Claytor (HRSA)

## Liaison Representatives

- Lynn Fisher (AAFP)
- Monica Ardura (AAP/COID)

- Jason Goldman (ACP)
- Saba Hasan (ACP, alternate)
- James McAuley (IDSA)
- Eva Wong (NACI)
- Robert Hopkins (NFID, primary)
- William Schaffner (NFID, alternate)
- Michelle Floris-Moore (NMA)
- Mary Hayney (APhA)

## Consultants

- Monica Farley (Emory)
- Keith Klugman (Gates Foundation)
- Kathy Poehling (Wake Forest)
- Arthur Reingold (UC Berkley)
- Lorry Rubin (CCMC)
- Richard Zimmerman (U. of Pittsburgh)

# CDC Contributors

## **Arctic Investigations Program**

- Heather Scobie

## **CDC Lead**

- Miwako Kobayashi

## **Division of Bacterial Diseases**

- Adam Cohen
- Ryan Gierke
- Noele Nelson

## **Immunization Safety Office**

- Pedro Moro

## **Immunization Services Division**

- Nancy Wong

# Pneumococcal Work Group Terms of Reference

- Review evidence to inform use of new pneumococcal conjugate vaccines in U.S. adults and children

# History of US Pneumococcal Vaccine Program, 1984–2024


**PPSV23:** adults aged ≥65 years and individuals with underlying conditions

**PCV13:** Adults with immunocompromising conditions

**PCV13:** All adults aged ≥65

**PCV13 based on SCDM** for all adults aged ≥65 years

**PCV21:** Adults



PCV=pneumococcal conjugate vaccine, PPSV23=23-valent pneumococcal polysaccharide vaccine, SCDM=shared clinical decision-making

# Current gaps in pneumococcal vaccine recommendations

- **Pregnant women**
  - Currently no recommendation

Vaccine	Pregnancy	Immuno-compromised (excluding HIV infection)	HIV infection CD4 percentage and count		Men who have sex with men	Asplenia, complement deficiency	Heart or lung disease	Kidney failure, End-stage renal disease or on dialysis	Chronic liver disease; alcoholism <sup>a</sup>	Diabetes	Health care Personnel <sup>b</sup>
			<15% or <200/mm <sup>3</sup>	≥15% and ≥200/mm <sup>3</sup>							
<a href="#">Pneumococcal</a> i											

Legend

Recommended for all adults who lack documentation of vaccination, <b>OR</b> lack evidence of immunity	Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease	Recommended vaccination based on shared clinical decision-making	Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes.	Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction	Contraindicated or not recommended *Vaccinate after pregnancy, if indicated	No Guidance/Not Applicable
---	---	--	---	--	--	----------------------------

# Current gaps in pneumococcal vaccine recommendations

- **Hematopoietic Stem Cell Transplant (HSCT) recipients**
  - Different vaccination schedule compared with other risk conditions (last updated in 2023)
  - No clinical guidance for PCV21 use

# Proposed work plan

- **Review of literature on pneumococcal vaccine use in pregnant women and HSCT recipients focusing on data on:**
  - Pneumococcal disease incidence and serotype distribution
  - Vaccine efficacy, effectiveness, and impact
  - Immunogenicity
  - Safety
- **Plan to present summary of findings and proposed language for updated clinical guidance on pneumococcal vaccine use at the [June 2025 ACIP meeting](#)**



# Thank you!

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [cdc.gov](https://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U. S. Centers for Disease Control and Prevention.